Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva formulación de netilmicina para el tratamiento de infecciones nosocomiales

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOTR20150731002
Publicado:
08/02/2016
Caducidad:
08/02/2017
Resumen:
Una universidad turca ha desarrollado una formulación para el tratamiento de infecciones nosocomiales. Las infecciones adquiridas en hospitales están muy extendidas en todo el mundo y están asociadas al incremento de la mortalidad y morbilidad, además de prolongar la estancia de los pacientes en el hospital y aumentar los costes de los tratamientos. Esta formulación, preparada mediante secado por pulverización, se basa en el uso netilmicina en los pulmones, actuando de forma rápida y segura. La universidad busca apoyo financiero para llevar a cabo los ensayos clínicos o licenciar la formulación.

Details

Tittle:
A new netilmicin formulation for treatment of hospital-acquired infection
Summary:
A Turkish university has developed an invention for nosocomial infection treatment. The researchers have developed a new drug formulation in order to shorten the treatment period. The university is looking for collaboration with financial support for clinical trials or via the licensing of the formulation.
Description:
The new netilmicin formulation has been developed by the research group from a Turkish university. Hospital acquired
infections are most common nosocomial infection in the worldwide and is associated with high mortality and morbidity. That increases the length of stay of patients in hospital and treatment costs. In this case, that burden to the national economy, a high rate of morbidity, mortality causes. Pneumonia is the second most common hospital-associated infection due to nosocomial pneumonia took the first place in intensive care unit infections. For this reason, in recent years, especially in developing countries, pneumonia has become a major issue discussed intensively on search for a solution to the disease.
The invention is aimed to treatment of hospital-acquired pneumonia infections by using netilmicin agent of the target area (lungs) acting quickly and reliably reach dry powder inhaler is the preparation of therapeutic formulations.
The new formulation was prepared by the spray drying method. Characterization studies were performed on the micro particles and powders. In vitro release profiles, the release kinetics analysis and stability studies were carried out. Animal experiments were performed with multi drug resistance p. aeruginosa and a. baumannii isolates that are obtained from patients of a cooperated hospital. Efficiency of the formulations was determined microbiologically and histopathologically. Preclinical studies have been completed, clinical trials will be conducted.
The university is looking for partners to have clinical trials completed. The partner could be a financial support provider or a company for license agreement.
Advantages and Innovations:
User benefits according to current treatments:
-Reduce the nebulizer usage of patients.
-The nebulizer originating contamination is reduced.
-Patients can have personal treatment chance.
-Outpatient treatment also offers the possibility of early discharge.
-Shorten the duration of treatment.
-It slows down the development of resistance against antibiotics.
Manufacturer benefits:
-One-step and quick production.
-High yields of product are obtained.
-The product has high stability and long shelf life.
-The product licensing process can be shorter, because the formulation contains a known active substance.
-It is a drug that enters the reimbursement system.
-High export potential is available.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application is made for Turkey but not yet granted.

Partner sought

Type and Role of Partner Sought:
- Type of partner sought:
Pharmeceutical industry, R-Y-D centre or universities

- Task to be performed by the partner sought:
Finishing the clinical trials or financial support for further development of the formula.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos